Zymeworks Begins Trial for Promising Cancer Therapy
ZymeWorks Has Dosed The First Patient In The First-In-Human Phase 1 Trial To Evaluate The Safety And Tolerability Of The Investigational Therapy ZW171 For Advanced Or Metastatic Ovarian Cancer, NSCLC, And Other MSLN-expressing Cancers
Express News | Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
Zymeworks Announces Board Changes With New Appointments
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
Maintaining Neutral: Hold Rating on Zymeworks Amidst Preclinical Progress and Upcoming Catalysts
Express News | Zymeworks, Inc. : H.c. Wainwright Raises Target Price to $12 From $10
Cancer Research Sees Major Boost as New Breakthroughs Emerge From Key Oncology Players
HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $10 Price Target
Zymeworks to Showcase New Cancer Treatments at Major Conference
Zymeworks' Hold Rating Amidst Promising Data and Competitive HER2+ GEA Treatment Landscape
Zymeworks Announced Two Presentations Highlighting Results From Recent Preclinical Research For Zymeworks' Antibody-drug Conjugate Candidates ZW220 And ZW251
Some Confidence Is Lacking In Zymeworks Inc.'s (NASDAQ:ZYME) P/S
Stifel Maintains Zymeworks(ZYME.US) With Buy Rating, Maintains Target Price $21
Stifel analyst Stephen Willey maintains $Zymeworks(ZYME.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of 41.4% and a total
Stifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)
Zymeworks Appoints New EVP and CFO; Leadership Transition
Express News | Zymeworks - on August 30, Kenneth Galbraith Resigned From Positions of Interim CFO and as Principal Financial Officer and Principal Accounting Officer
Zymeworks Engages Investors, Awaits Drug Approval
Zymeworks Announces Participation in Upcoming Investor Conferences
Buy Rating on Zymeworks Stock Amid Anticipated Zani Approval and Strategic Capital Allocation